Bacteriophages are viruses that specifically target and destroy bacteria while leaving human and animal cells unharmed. Due to this distinctive capability, scientists consider them as a promising alternative for combating antibiotic-resistant bacterial infections. Currently, no phage therapy products have been approved for human use in either the EU or the United States.
The company we are profiling today is Armata Pharmaceuticals (ARMP), a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections. Its phage product candidates include AP-PA02 and AP-SA02.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com